# Treatment Options for Systemic Amyloidosis
The treatment of systemic amyloidosis is aimed at two goals: stopping the production of harmful proteins and relieving symptoms caused by amyloid deposits in organs. Which treatment is appropriate depends on the type of amyloidosis, which organs are affected, and how far the disease has progressed.
Treatment of Light Chain Amyloidosis (AL Amyloidosis)
Cytostatic Treatment
In AL amyloidosis, the goal is to eliminate bone marrow cells that produce faulty proteins. This is usually achieved with combinations of chemotherapy and targeted agents.
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Bortezomib in combination with alkylating agents and dexamethasone* forms the basis of many treatment regimens. Bortezomib inhibits a cellular processing machine (the proteasome), causing abnormal cells to die. This is supplemented with cytostatic drugs such as melphalan and short-term dexamethasone. This approach shows demonstrable remission in a large proportion of newly diagnosed patients. Known side effects include nerve damage to the hands and feet (peripheral neuropathy), fatigue, and blood system effects. Recent research points to caution with long-term dexamethasone use due to accumulated toxicity.
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Daratumumab* is a monoclonal antibody directed against certain bone marrow cells. It is increasingly being added to standard regimens, especially for newly detected patients. The combination improves outcomes. Possible side effects include infusion-related reactions, infections, and fatigue.
ResearchediPositive results in clinical studies, not yet standard treatment
*Trispecific antibodies* are newer immunotherapies (including those targeting BCMA and GPRC5D) currently being tested in clinical trials for AL amyloidosis. These agents activate the immune system to attack cancer cells via multiple routes simultaneously. Studies are ongoing, but initial results are encouraging.
ResearchediPositive results in clinical studies, not yet standard treatment
*Sonrotoclax* is an experimental agent being investigated in combination with dexamethasone and possibly daratumumab, especially for patients with specific genetic abnormalities (t(11;14) translocation). This aims to cause the collapse of protective proteins in abnormal cells.
Stem Cell Transplantation
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Autologous stem cell transplantation* (reinfusion of own stem cells after intensive chemotherapy) is considered for selected patients with good cardiac tolerance and preparation. This can provide long-term remission. The risk lies in intensive side effects, infections, and cardiac failure during recovery. This is no longer standard treatment for all AL patients, but may offer benefit for certain groups.
Treatment of Hereditary Transthyretin Amyloidosis (ATTR Amyloidosis)
Stabilizers
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Tafamidis* is an agent that stabilizes the transthyretin protein, preventing it from breaking down and forming amyloid. This demonstrably slows the progression of nerve damage and cardiac muscle involvement. Side effects are mild; peripheral swelling and fluid retention can occur.
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Diflunisal* (an anti-inflammatory) also stabilizes transthyretin, but is used less often due to the risk of kidney disease with long-term use.
Protein Synthesis Inhibitors
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Inotersen and patisiran* are two different molecular approaches that reduce the production of the harmful transthyretin protein. Inotersen is an antisense oligonucleotide (an artificial RNA fragment) that blocks the transthyretin message in cells. Patisiran uses RNA interference ('gene silencing'). Both demonstrably slow neurological deterioration. Inotersen can cause inflammation and blood system problems; patisiran requires regular infusions.
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Voxelotor* (currently less commonly used than the agents mentioned above) is another protein synthesis inhibitor being investigated for certain ATTR forms.
Supportive Treatment
Cardiac Protection
ProveniIncluded in official guidelines, or approved by EMA or FDA
In patients with cardiac involvement (amyloid cardiomyopathy), classic heart medications are used: ACE inhibitors or angiotensin receptor blockers for blood pressure control, and beta blockers for heart rate slowing. These don't breathe away amyloid mass, but help the heart work more efficiently despite the deposits.
ProveniIncluded in official guidelines, or approved by EMA or FDA
*Diuretics* (water pills) relieve fluid buildup and shortness of breath. Careful dosing is essential because the heart of amyloidosis patients is sensitive to changes in fluid balance.
Kidney protection
ProveniIncluded in official guidelines, or approved by EMA or FDA
In kidney involvement (amyloid nephropathy), secretion-reducing agents are used: ACE inhibitors or angiotensin-II receptor blockers. These slow kidney function loss. In severe kidney failure, dialysis may be needed.
Symptomatic treatment
ProveniIncluded in official guidelines, or approved by EMA or FDA
For nerve pain (neuropathy), painkillers and sometimes anticonvulsants are used. For diarrhea or heart rhythm problems, specific medications are available that relieve symptoms without addressing the underlying amyloidosis.
Diagnostic and imaging approaches in development
ResearchediPositive results in clinical studies, not yet standard treatment
*MRI mapping and high-resolution MRI sequences* (including the AMYLOCARP study) are being investigated to detect amyloid deposits more accurately and earlier in wrists and other areas. This can improve future diagnosis.
ResearchediPositive results in clinical studies, not yet standard treatment
*99mTc-p5+14* is an experimental radioactive tracer that makes amyloid locations in the body visible. This is still in the testing phase with healthy volunteers and patients.
Monitoring and follow-up treatment
Regardless of amyloidosis type, regular monitoring takes place through blood tests (the harmful protein is measured), kidney function, heart ultrasound and possibly other imaging. This determines whether treatment helps and if adjustments are needed. Some patients achieve complete response and can have long remission periods; others need ongoing treatment.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._